Aktuelle klinische Studie am American College of Cardiology unterstützt niedrig dosiertes Colchicin (0,5 mg) zur Behandlung von Herz-Kreislauf-Erkrankungen durch Verringerung der Fortschreitung der Koronarplaquebildung

PARSIPPANY, N.J.–(BUSINESS WIRE)–AGEPHA Pharma USA, LLC, is pleased to highlight clinical data that provides new information about how low-dose colchicine, 0.5 mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. The study titled, “Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients […]

Steve Andrzejewski

Co-Vorsitzender des Vorstands

Biografie